BCDA Earnings

BCDA reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 50.00K, resulting in a -100% surprise. The EPS was -0.24, surpassing the expected -0.25 by 4%. The stock experienced a -3.08% price change on the earnings day and a -0.77% change over the next five days, reflecting market reactions to the results.

Following BCDA's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -3.08% on the day of the release. Over the subsequent five days, it saw a -0.77% change. Historically, BCDA's stock price tends to shift by an average of 6.25% in the 10 days leading up to earnings and -7.45% in the 10 days following, providing insight into potential market.

For , analysts estimate BCDA's annual revenue to reach , while the EPS is projected at -0.23. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BCDA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BCDA's stock price typically moves by 6.25% in the 10 days before its earnings and -7.45% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.23 and revenue of .

The earnings call reveals mixed sentiments: increased R&D expenses and operational costs are concerning, but the CardiAMP HF's potential FDA approval and competitive advantage offer optimism. The Q&A highlights slow trial enrollment and non-significant p-values, but also potential regulatory success and partnership interest. The absence of strong financial guidance and the challenge of rising costs balance the positive aspects, leading to a neutral outlook for the stock price over the next two weeks.